Baseline characteristics of the patient cohort
| . | Clopidogrel group (n = 20) . | Ticagrelor group (n = 20) . | P . |
|---|---|---|---|
| Age, mean ± standard deviation, y | 73.2 ± 11.2 | 63.1 ± 11.7 | .008 |
| Female sex, no (%) | 9/20 (45) | 4/20 (20) | .09 |
| History, CV risk factors, n (%) | |||
| Previous MI | 4/20 (25) | 3/20 (15) | .68 |
| History of CAD | 4/20 (20) | 5/20 (25) | .71 |
| History of PAD | 2/20 (10) | 1/20 (5) | .55 |
| Diabetes mellitus | 3/20 (15) | 6/20 (30) | .26 |
| Current smoker | 2/20 (10) | 3/20 (15) | .63 |
| Arterial hypertension | 18/20 (90) | 17/20 (85) | .63 |
| Hyperlipidemia | 6/20 (30) | 8/20 (40) | .51 |
| Medication, n (%) | |||
| ACE-I/ARB | 17/20 (85) | 20/20 (100) | .07 |
| Lipid lowering agents | 16/20 (80) | 19/20 (95) | .15 |
| β blocker | 15/20 (75) | 19/20 (95) | .08 |
| MRA | 3/20 (15) | 3/20 (15) | 1.0 |
| PPI | 10/20 (50) | 6/20 (30) | .20 |
| Procedural characteristics | |||
| Stent implantation, n (%) | 14/20 (70) | 18/20 (90) | .114 |
| DES only, n (%) | 14/14 (100) | 18/18 (100) | |
| Normal LV function (EF > 55%), n (%) | 11/20 (55) | 9/20 (45) | .27 |
| Moderately reduced LV function (EF 45-55%), n (%) | 8/20 (40) | 10/20 (50) | |
| Severely reduced LV function (EF<35%), n (%) | 1/20 (5) | 1/20 (5) | |
| Bleeding complication, n (%) | 0/20 (0) | 0/20 (0) | 1.0 |
| Renal function Baseline CrCl, mean ± standard deviation, mL/min | 78.4 ± 23.3 | 82.8 ± 28.1 | .60 |
| Baseline C-reactive protein, mg/dL | 0.74 ± 0.9 | 1.86 ± 4.25 | .26 |
| INR, baseline | 1.1 ± 0.08 | 1.1 ± 0.05 | .36 |
| Platelet count, mean ± standard deviation, ×109/L | 227 ± 54.5 | 239 ± 74.7 | .59 |
| . | Clopidogrel group (n = 20) . | Ticagrelor group (n = 20) . | P . |
|---|---|---|---|
| Age, mean ± standard deviation, y | 73.2 ± 11.2 | 63.1 ± 11.7 | .008 |
| Female sex, no (%) | 9/20 (45) | 4/20 (20) | .09 |
| History, CV risk factors, n (%) | |||
| Previous MI | 4/20 (25) | 3/20 (15) | .68 |
| History of CAD | 4/20 (20) | 5/20 (25) | .71 |
| History of PAD | 2/20 (10) | 1/20 (5) | .55 |
| Diabetes mellitus | 3/20 (15) | 6/20 (30) | .26 |
| Current smoker | 2/20 (10) | 3/20 (15) | .63 |
| Arterial hypertension | 18/20 (90) | 17/20 (85) | .63 |
| Hyperlipidemia | 6/20 (30) | 8/20 (40) | .51 |
| Medication, n (%) | |||
| ACE-I/ARB | 17/20 (85) | 20/20 (100) | .07 |
| Lipid lowering agents | 16/20 (80) | 19/20 (95) | .15 |
| β blocker | 15/20 (75) | 19/20 (95) | .08 |
| MRA | 3/20 (15) | 3/20 (15) | 1.0 |
| PPI | 10/20 (50) | 6/20 (30) | .20 |
| Procedural characteristics | |||
| Stent implantation, n (%) | 14/20 (70) | 18/20 (90) | .114 |
| DES only, n (%) | 14/14 (100) | 18/18 (100) | |
| Normal LV function (EF > 55%), n (%) | 11/20 (55) | 9/20 (45) | .27 |
| Moderately reduced LV function (EF 45-55%), n (%) | 8/20 (40) | 10/20 (50) | |
| Severely reduced LV function (EF<35%), n (%) | 1/20 (5) | 1/20 (5) | |
| Bleeding complication, n (%) | 0/20 (0) | 0/20 (0) | 1.0 |
| Renal function Baseline CrCl, mean ± standard deviation, mL/min | 78.4 ± 23.3 | 82.8 ± 28.1 | .60 |
| Baseline C-reactive protein, mg/dL | 0.74 ± 0.9 | 1.86 ± 4.25 | .26 |
| INR, baseline | 1.1 ± 0.08 | 1.1 ± 0.05 | .36 |
| Platelet count, mean ± standard deviation, ×109/L | 227 ± 54.5 | 239 ± 74.7 | .59 |
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CrCl, creatinine clearance according to Modification of Diet in Renal Disease formula; DES, drug-eluting stents; EF, ejection fraction; INR, international normalized ratio; MI, myocardial infarction; LV-function, left-ventricular function; MRA, mineralocorticoid receptor antagonists; PAD, peripheral artery disease; PPI, proton pump inhibitors.